Clinical trials · Dallas–Fort Worth, TX
Ulcerative Colitis clinical trials in Dallas–Fort Worth
We’re tracking 20 recruiting ulcerative colitis studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT02791854Enrolling by invitation
Improving Care for Adults With Crohn’s or Ulcerative Colitis
This trial looks at ways to improve care for adults living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. You may be invited if your clinic is part of an inflammatory bowel disease care network called IBD Qorus.
Dallas, TexasAges 18–99 - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Dallas, TexasAges 18–80 - NCT07113522RecruitingPhase 2
Study of new therapies for Crohn's and colitis
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Dallas, TexasAges 18–80 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Dallas, TexasAges 16–80 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Dallas, TexasAges 18 years+ - NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Dallas, TexasAges 18–65 - NCT05230173Recruiting
Treat to endoscopic remission in inflammatory bowel disease
This study tests whether switching to a different treatment for inflammatory bowel disease (IBD) can achieve healing of the gut lining. It is for people whose symptoms are under control but who still have significant inflammation in their bowel.
Dallas, TexasAges 18 years+ - NCT06619990RecruitingPhase 1/Phase 2
Study of XmAb942 for active ulcerative colitis
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Garland, TexasAges 18–75 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Garland, TexasAges 18–75 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Garland, TexasAges 18–80 - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Garland, TexasAges 16–80 - NCT06029972RecruitingPhase 2
Experimental drug for moderate to severe ulcerative colitis
This trial tests an experimental medication (tilpisertib fosmecarbil) for people with moderate to severe ulcerative colitis who have already tried at least one advanced therapy but it didn't work well enough. The study aims to see if this new drug can help reduce inflammation and improve symptoms.
Garland, TexasAges 18–75 - NCT06651281RecruitingPhase 3
Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
Garland, TexasAges Any age - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Carrollton, TexasAges 12 years+ - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
Southlake, TexasAges 18–64 - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Southlake, TexasAges 16–80 - NCT06867094RecruitingPhase 2
Study of SAR441566 for Ulcerative Colitis
This trial tests a new medicine called SAR441566 for people with moderate-to-severe ulcerative colitis (UC). It may help reduce symptoms like bleeding and diarrhea if other treatments haven't worked well enough.
Southlake, TexasAges 18–75 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Fort Worth, TexasAges 2–17 - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Fort Worth, TexasAges 2–19 - NCT07686757Enrolling by invitationPhase 4
Study of mirikizumab for ulcerative colitis and Crohn's disease
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Fort Worth, TexasAges 21 years+
Hear when a new Ulcerative Colitis trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Ulcerative Colitis trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- GI Alliance · 6 studies
- GI Alliance - Southlake · 5 studies
- Texas Digestive Disease Consultants · 3 studies
- University of Texas Southwestern Medical Center · 3 studies
- Cook Children's Medical Center
- DFW Clinical Trials
- Digestive Health Associates of Texas (DHAT) Research Institute
- GI Alliance - Dallas
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting ulcerative colitis studies in Texas.
Common questions
- Are there ulcerative colitis clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 20 recruiting ulcerative colitis studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.